Trade Merck KGaA - EUR - MRKd CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.45
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.017307 %(-€0.87)Trade size with leverage ~ €5,000.00Money from leverage ~€4,000.00Go to platform: -0.01731%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.004915 %(-€0.25)Trade size with leverage ~ €5,000.00Money from leverage ~€4,000.00Go to platform: -0.00492%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 0.1
• Margin: 20.00%
• Stock exchange: Germany
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.017307 %
  (-€0.87)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.004915 %
  (-€0.25)

Key Stats

• Prev. Close: 144.3
• Open: 143.85
• 1-Year Change: 27.24%
• Day's Range: 143.3 - 144.1

Trade Merck KGaA - EUR - MRKd

About Merck KGaA

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Merck KGaA revenues increased 12% to EUR19.69B. Net income applicable to common stockholders increased 54% to EUR3.06B. Revenues reflect Life Science segment increase of 20% to EUR8.99B, Healthcare segment increase of 7% to EUR7.09B, United States (Country) segment increase of 13% to EUR5.25B, Rest of Europe segment increase of 14% to EUR4.03B.

Equity composition

2003 Q1 has been restated to reflect discontinued operations. 01/2007, Rights Issue, 4 new shares for every 29 shares held @ EUR 78 (Factor: 1.015602). 6/2014, 2-for-1 stock split (Factor: 2).